The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Artificial intelligence (AI)-based drug developer Recursion said it has completed the fastest supercomputer to be wholly owned and operated by any pharmaceutical company worldwide, using technology ...

One reason Recursion Pharmaceuticals could become a big deal is that its goal is to usher a paradigm shift into the pharmaceutical industry. Even with impressive technological progress over the past ...

Recursion stands out as a pure play in AI-powered biotech, using machine learning algorithms to accelerate drug research and development (R&D). The company's BioHive-2 supercomputer, powered by Nvidia ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

Chipmaker Nvidia will invest $50 million in Recursion Pharmaceuticals to speed up the development of the biotech firm's artificial intelligence models for drug discovery. Salt Lake City, Utah-based ...